Pancreatic Cancer Research

ResearcherUniversity of Yamanashi HospitalActive in the last 2 years

Hiromichi Kawaida

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3507-0167; OpenAlex author ID A5062824750. Sources: OpenAlex.

Their work

Papers
13 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
16
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: none · 2021: 3 papers · 2022: none · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper · 2026: 3 papers

Papers 13

  1. To Evaluate Whether Pretreatment CA19-9 and DUPAN-2 Levels Can Serve as Predictive Markers to Guide the Choice Between NAT and Upfront Surgery in Pancreatic Ca… Co-author DOI 10.1002/ags3.70140↗
  2. The post-neoadjuvant absolute lymphocyte count reflects the pathological response and local tumor control in pancreatic cancer. Co-author DOI 10.1007/s00595-026-03412-y↗
  3. Prognostic Significance of Extrapancreatic Invasion in Pancreatic Cancer: Excellent Outcomes in Patients With Disease Confined Within the Pancreas. Co-author DOI 10.21873/anticanres.18011↗
  4. Prognostic Significance of Splenic Vein Invasion for Pancreatic Cancer Patients With Pancreatectomy: A Retrospective Study. Co-author DOI 10.21873/anticanres.17465↗
  5. Re-consideration of Lymph Node Metastasis in Pancreatic Cancer Patients Following Radical Resection: A Retrospective Study. First author DOI 10.21873/anticanres.17020↗
  6. Predictors of the therapeutic effect of Nab-paclitaxel plus gemcitabine therapy for patients with recurrent pancreatic cancer after pancreatectomy Co-author DOI 10.21203/rs.3.rs-3201226/v1↗
  7. Cytoglobin as a Prognostic Factor for Pancreatic Ductal Adenocarcinoma: A Retrospective Analysis of 75 Patients. Co-author DOI 10.1097/mpa.0000000000001871↗
  8. Exposure to Blood Components and Inflammation Contribute to Pancreatic Cancer Progression. First author DOI 10.1245/s10434-021-10250-4↗
  9. High-performance Collective Biomarker from Liquid Biopsy for Diagnosis of Pancreatic Cancer Based on Mass Spectrometry and Machine Learning. Co-author DOI 10.7150/jca.63244↗
  10. Diffusion-weighted image improves detectability of magnetic resonance cholangiopancreatography for pancreatic ductal adenocarcinoma concomitant with intraducta… Co-author DOI 10.1097/md.0000000000018039↗
  11. Mutational Patterns in Pancreatic Juice of Intraductal Papillary Mucinous Neoplasms and Concomitant Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001371↗
  12. Feasibility of Combination Therapy with Nab-paclitaxel Plus Gemcitabine in Patients with Recurrent Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13019↗
  13. [Prognostic factors for long-term survival in patients with pancreatic ductal adenocarcinoma]. Co-author PMID 25857011↗

Closest collaborators

The 16 strongest of 16 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daisuke Ichikawa · 11 shared papers, 2018–2026 · strength 1.86
  2. Wataru Izumo · 5 shared papers, 2024–2026 · strength 1.23
  3. Ryo Saito · 3 shared papers, 2026 · strength 0.83
  4. Ryo Saito · 5 shared papers, 2021–2025 · strength 0.76
  5. Hiroshi Kono · 5 shared papers, 2018–2023 · strength 0.52
  6. Shinichi Takano · 4 shared papers, 2018–2023 · strength 0.35
  7. Hideki Fujii · 3 shared papers, 2015–2023 · strength 0.31
  8. Satoshi Kawakami · 3 shared papers, 2019–2023 · strength 0.29
  9. Nobuyuki Enomoto · 3 shared papers, 2019–2023 · strength 0.29
  10. Makoto Kadokura · 2 shared papers, 2019 · strength 0.15
  11. Shintaro Ichikawa · 2 shared papers, 2018–2019 · strength 0.13
  12. Sho Kiritani · 1 shared paper, 2021 · strength 0.12
  13. Genki Watanabe · 1 shared paper, 2021 · strength 0.12
  14. Tomohiko Iwano · 1 shared paper, 2021 · strength 0.12
  15. Sén Takeda · 1 shared paper, 2021 · strength 0.12
  16. Hiroshi Onishi · 1 shared paper, 2019 · strength 0.07

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.